Scholarlink

Backgroud <p>The benefit of adjuvant chemotherapy for patients with stage IB lung adenocarcinoma remains unclear. We compared adjuvant chemotherapy outcomes in Asian and non-Asian stage IB lung adenocarcinoma patients using multi-source clinical data.</p> Methods <p>Patients with stage IB lung adenocarcinoma from the 2004–2015 Surveillance, Epidemiology, and End Results (SEER) database and the 2020–2021 thoracic surgery department of three Chinese medical centers were included. Patients were divided into adjuvant chemotherapy and observation groups. Propensity score matching (PSM) was performed to reduce confounding bias. Survival curves were plotted and compared using the Kaplan–Meier method and log-rank test, respectively.</p> Results <p>In the SEER data, 3408 patients met the inclusion criteria, overall survival (OS) was significantly better in the adjuvant chemotherapy group than in the observation group. In the non-Asian population, OS was significantly better in the adjuvant chemotherapy group, both before and after PSM. In the Asian population, OS did not significantly differ between the two groups before or after PSM. Among 690 patients from the three centers, disease-free survival (DFS) and OS in the adjuvant chemotherapy group were not better than those in the observation group, before or after PSM and in patients with high pathological grade or visceral pleural infiltration (VPI).</p> Conclusions <p>Adjuvant chemotherapy can significantly improve the prognosis of non-Asian patients with stage IB lung adenocarcinoma. In Asian patients, adjuvant chemotherapy does not improve prognosis, even in patients with high pathological grade or VPI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Limited benefit of adjuvant chemotherapy for Asian patients with stage IB lung adenocarcinoma: implications for clinical practice

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月7日

查看全文
  • Shaowei Xin,
  • Jie Li,
  • Long Jiang,
  • Jianfei Zhu,
  • Jie Lei,
  • Jinbo Zhao,
  • Miaomiao Wen,
  • Yahui Tian,
  • Zitong Wan,
  • Yujie Guo,
  • Yinxi Zhou,
  • Suxin Jiang,
  • Chunlong Zheng,
  • Yong Han,
  • Yongfu Ma,
  • Yanlu Xiong

摘要

Backgroud

The benefit of adjuvant chemotherapy for patients with stage IB lung adenocarcinoma remains unclear. We compared adjuvant chemotherapy outcomes in Asian and non-Asian stage IB lung adenocarcinoma patients using multi-source clinical data.

Methods

Patients with stage IB lung adenocarcinoma from the 2004–2015 Surveillance, Epidemiology, and End Results (SEER) database and the 2020–2021 thoracic surgery department of three Chinese medical centers were included. Patients were divided into adjuvant chemotherapy and observation groups. Propensity score matching (PSM) was performed to reduce confounding bias. Survival curves were plotted and compared using the Kaplan–Meier method and log-rank test, respectively.

Results

In the SEER data, 3408 patients met the inclusion criteria, overall survival (OS) was significantly better in the adjuvant chemotherapy group than in the observation group. In the non-Asian population, OS was significantly better in the adjuvant chemotherapy group, both before and after PSM. In the Asian population, OS did not significantly differ between the two groups before or after PSM. Among 690 patients from the three centers, disease-free survival (DFS) and OS in the adjuvant chemotherapy group were not better than those in the observation group, before or after PSM and in patients with high pathological grade or visceral pleural infiltration (VPI).

Conclusions

Adjuvant chemotherapy can significantly improve the prognosis of non-Asian patients with stage IB lung adenocarcinoma. In Asian patients, adjuvant chemotherapy does not improve prognosis, even in patients with high pathological grade or VPI.